Suppr超能文献

通过微型聚合物-药物微阵列提高吡唑并[3,4-]嘧啶衍生物的水溶性

Water Solubility Enhancement of Pyrazolo[3,4-]pyrimidine Derivatives via Miniaturized Polymer-Drug Microarrays.

作者信息

Sanna Monica, Sicilia Giovanna, Alazzo Ali, Singh Nishant, Musumeci Francesca, Schenone Silvia, Spriggs Keith A, Burley Jonathan C, Garnett Martin C, Taresco Vincenzo, Alexander Cameron

机构信息

Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV 3, 16132 Genova, Italy.

School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, U.K.

出版信息

ACS Med Chem Lett. 2018 Jan 29;9(3):193-197. doi: 10.1021/acsmedchemlett.7b00456. eCollection 2018 Mar 8.

Abstract

A miniaturized assay was optimized to evaluate the enhanced apparent water solubility of pyrazolo[3,4-]pyrimidine derivatives used extensively as anticancer drug scaffolds. The applied amount of drugs used in the reported strategy ranged from 5 to 10 μg per formulation which were dispensed by an inkjet 2D printer directly into a 96-well plate. The selected polymer/drug formulations with high water solubility demonstrated improved cytotoxicity against a human lung adenocarcinoma cancer cell line (A549) compared to the free drugs. We attribute the enhanced efficacy to the improved apparent-solubility of the drug molecules achieved via this methodology. This novel miniaturized method showed promising results in terms of water solubility improvement of the highly hydrophobic pyrazolo[3,4-]pyrimidine derivatives, requiring only a few micrograms of each drug per tested polymeric formulation. In addition, the reported experimental evidence may facilitate identification of suitable polymers for combination with drug, leading to investigations on biological properties or mechanisms of action in a single formulation.

摘要

一种小型化检测方法得到了优化,以评估广泛用作抗癌药物支架的吡唑并[3,4 -]嘧啶衍生物增强的表观水溶性。所报道策略中使用的药物用量为每制剂5至10微克,通过喷墨二维打印机直接分配到96孔板中。与游离药物相比,所选的具有高水溶性的聚合物/药物制剂对人肺腺癌细胞系(A549)表现出更高的细胞毒性。我们将疗效增强归因于通过该方法实现的药物分子表观溶解度的提高。这种新颖的小型化方法在提高高度疏水的吡唑并[3,4 -]嘧啶衍生物的水溶性方面显示出有前景的结果,每个测试的聚合物制剂仅需要几微克的每种药物。此外,所报道的实验证据可能有助于识别与药物组合的合适聚合物,从而对单一制剂中的生物学性质或作用机制进行研究。

相似文献

1
Water Solubility Enhancement of Pyrazolo[3,4-]pyrimidine Derivatives via Miniaturized Polymer-Drug Microarrays.
ACS Med Chem Lett. 2018 Jan 29;9(3):193-197. doi: 10.1021/acsmedchemlett.7b00456. eCollection 2018 Mar 8.
4
Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.
ACS Med Chem Lett. 2013 May 20;4(7):622-6. doi: 10.1021/ml4000782. eCollection 2013 Jul 11.
5
Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
Mol Pharm. 2018 Jun 4;15(6):2355-2371. doi: 10.1021/acs.molpharmaceut.8b00206. Epub 2018 May 4.
6
Rapid Nanogram Scale Screening Method of Microarrays to Evaluate Drug-Polymer Blends Using High-Throughput Printing Technology.
Mol Pharm. 2017 Jun 5;14(6):2079-2087. doi: 10.1021/acs.molpharmaceut.7b00182. Epub 2017 May 19.
8
Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Int J Pharm. 2012 Apr 15;426(1-2):219-230. doi: 10.1016/j.ijpharm.2012.01.027. Epub 2012 Jan 24.
10
Development of Pyrazolo[3,4-]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.
ACS Med Chem Lett. 2020 Feb 13;11(5):657-663. doi: 10.1021/acsmedchemlett.9b00530. eCollection 2020 May 14.

引用本文的文献

2
3
.
Cancers (Basel). 2020 Jun 12;12(6):1558. doi: 10.3390/cancers12061558.
4
Development of Pyrazolo[3,4-]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.
ACS Med Chem Lett. 2020 Feb 13;11(5):657-663. doi: 10.1021/acsmedchemlett.9b00530. eCollection 2020 May 14.

本文引用的文献

2
Rapid Nanogram Scale Screening Method of Microarrays to Evaluate Drug-Polymer Blends Using High-Throughput Printing Technology.
Mol Pharm. 2017 Jun 5;14(6):2079-2087. doi: 10.1021/acs.molpharmaceut.7b00182. Epub 2017 May 19.
5
Fundamental aspects of solid dispersion technology for poorly soluble drugs.
Acta Pharm Sin B. 2014 Feb;4(1):18-25. doi: 10.1016/j.apsb.2013.11.001. Epub 2013 Dec 5.
9
Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.
ACS Med Chem Lett. 2013 May 20;4(7):622-6. doi: 10.1021/ml4000782. eCollection 2013 Jul 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验